Home » Stocks » AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc. (AMAG)

Stock Price: $10.55 USD 0.51 (5.08%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $10.95 +0.40 (3.79%) Aug 7, 7:24 PM

Stock Price Chart

Key Info

Market Cap 361.58M
Revenue (ttm) 297.70M
Net Income (ttm) -368.86M
Shares Out 34.27M
EPS (ttm) -7.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $10.55
Previous Close $10.04
Change ($) 0.51
Change (%) 5.08%
Day's Open 10.49
Day's Range 10.20 - 10.99
Day's Volume 466,602
52-Week Range 4.41 - 13.53

More Stats

Market Cap 361.58M
Enterprise Value 540.88M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.27M
Float 16.77M
EPS (basic) -10.87
EPS (diluted) -7.60
FCF / Share -2.40
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.32M
Short Ratio 20.45
Short % of Float 73.33%
Beta 1.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.21
PB Ratio 1.29
Revenue 297.70M
Operating Income -347.38M
Net Income -368.86M
Free Cash Flow -81.78M
Net Cash -179.30M
Net Cash / Share -5.23
Gross Margin 60.10%
Operating Margin -116.69%
Profit Margin -115.10%
FCF Margin -27.47%
ROA -6.30%
ROE -69.13%
ROIC -105.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 2
Overweight 0
Hold 5
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$8.18*
(-22.46% downside)
Low
5.00
Current: $10.55
High
10.00
Target: 8.18
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue32847449643241812480.8685.3861.2566.25
Revenue Growth-30.85%-4.39%14.63%3.4%236.28%53.83%-5.3%39.39%-7.54%-
Gross Profit22125833433633010468.9071.1650.7258.64
Operating Income-446-47.05-30485.08111-3.84-11.62-17.42-79.79-82.99
Net Income-466-65.76-199-2.4832.78136-9.60-16.75-77.07-81.15
Shares Outstanding34.0334.3934.9134.3531.4722.4221.7021.3921.1920.81
Earnings Per Share-13.71-1.91-5.71-0.070.935.45-0.44-0.78-3.64-3.90
EPS Growth-----82.94%-----
Operating Cash Flow-12660.8010724695.9811.41-6.77-1.16-63.80-1.53
Capital Expenditures-2.54-2.53-8.99-5.46-1.26-0.041.34-0.05-0.51-1.22
Free Cash Flow-12858.2797.6124194.7211.37-5.44-1.20-64.31-2.75
Cash & Equivalents172405300582469147217228213261
Total Debt301283735987992495----
Net Cash / Debt-129121-435-405-523-349217228213261
Assets7911,1751,9002,4782,4761,389265258267336
Liabilities5054291,1101,5441,54492993.0585.3486.6390.79
Book Value286747790934932460172173181245
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AMAG Pharmaceuticals, Inc.
Country United States
Employees 440
CEO Scott D. Myers

Stock Information

Ticker Symbol AMAG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AMAG

Description

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.